2628:HKEXChina Life Insurance Co. Ltd. Class H Analysis

China Life Insurance (2628.HK) trades at HK$29.4, delivering a trailing P/E of 4.3x versus an industry average of 17.2x, and a price‑to‑book of 1.17x. The stock offers a 2.64% dividend yield with a modest 10.8% payout ratio, underscoring dividend sustainability. Revenue surged 49.7% year‑over‑year and operating margins sit near 94%, reflecting strong profitability. Technicals show a bullish longer‑term trend (price above the 200‑day SMA) but a bearish short‑term signal: MACD is negative, the price sits below the 20‑day SMA, and RSI is around 39. Volume is increasing, supporting liquidity, while 30‑day volatility is elevated at 46%. The DCF model suggests a fair value of HK$235, implying a substantial upside, and analyst consensus projects a median target of HK$34.3 (+24% upside). Overall, the fundamentals are robust, valuation appears deeply discounted, and dividend income adds a defensive layer.
Given the low beta (0.26) and strong capital base, the stock’s risk profile is moderate, but regulatory and geographic concentration in China introduce medium‑level concerns. The bearish MACD and price below the short‑term SMA temper short‑term enthusiasm, yet the strong earnings growth, low valuation multiples, and attractive yield support a buy stance for medium to long horizons. Investors should monitor any policy shifts in China’s insurance sector and upcoming dividend dates, which could provide short‑term catalysts. The combination of solid fundamentals and significant upside potential makes China Life a compelling addition for value‑oriented portfolios seeking steady income.